Inspyr is developing prodrug therapeutics for some of the most challenging diseases in oncology, harnessing a cutting-edge platform technology to deliver a cytotoxin safely and efficiently directly to tumors.
Inspyr's proven executive management team from the pharmaceutical industry includes drug discovery, medical technology, life sciences, and clinical stage development. Our scientific team includes leading researchers and doctors from around the world.
Developed at Johns Hopkins University and the University of Copenhagen, Inspyr's patented technology platform that has the potential to work across a spectrum of drugs that precisely target different cancers.
New Prodrug Takes Aim at Recurrent Glioblastoma